In a presentation at the International Academy for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer in July 2011, VisionGate showed how LuCED harnesses the power of 3D imaging to accurately detect cancer cells in sputum samples from individuals at high-risk of lung cancer, without the use of x-rays. LuCED works with the company's automated Cell-CT platform to produce detailed 3D images of the cells contained in sputum samples, which the system automatically analyzes to identify key features, or biosignatures, associated with potential malignancy. The analysis yields a score that indicates whether or not cancer cells are present in the sample. The Cell-CT system produces strikingly clear and comprehensive 3D images of the cells, enabling extremely accurate classifications.
Separately, VisionGate reported that it has closed the first $1.96 million tranche of a projected $3 million equity financing. The financing included both existing and new investors.
Alan Nelson, PhD, chairman and CEO of VisionGate, commented, "We view the enthusiastic response to our current financing round as a testament to the broad potential of our innovative 3D cell imaging technology. These funds will enable us to continue to rapidly advance the clinical and regulatory development of LuCED and our 3D cell imaging platform."
About The Sheba Medical CenterThe Sheba Medical Center at Tel Hashomer is a university-affiliated tertiary referral hospital that serves as Israel's national medical center in many fields. Adjacent to Tel Aviv, it is the most comprehensive medical center in the Middle East, renowned for its compassionate care and leading-edge medicine. It is also a major medical-scientific research powerhouse that collaborates internationally with the biotech and pharmaceutical industries to
|SOURCE VisionGate, Inc.|
Copyright©2010 PR Newswire.
All rights reserved